findmyKOL
Clinical trialNCT06366347RecruitingPhase 2Interventional

ALPINE: Maintenance Letrozole/Abemaciclib

SponsorDana-Farber Cancer InstituteEnrollment32Endometrial CancerRecurrent Endometrial CancerTP53
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer. The names of the study drugs involved in this study are: * Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) * Letrozole (a type of aromatase inhibitor)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

    Meghan Shea, MD
    Recruiting
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    Panagiotis Konstantinopoulos, MD, PhD →
    Recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Panagiotis Konstantinopoulos, MD, PhD →
    Recruiting
  • Dana-Farber Cancer Institute at Foxborough

    Foxborough, Massachusetts, United States

    Withdrawn
  • Dana-Farber Cancer Institute at Milford

    Milford, Massachusetts, United States

    Withdrawn
  • Dana-Farber Cancer Institute at South Shore Hospital

    Weymouth, Massachusetts, United States

    Meredith Faggen, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abemaciclib →Letrozole →Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Sept 2024
Primary completion
1 Sept 2027
Completion
1 Mar 2029
Last update posted
11 Feb 2026
Registered enrollment
32
Registry id
NCT06366347
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.